Assessing Hims & Hers Health (HIMS) Valuation After Compounded GLP-1 Launch And Rapid Regulatory Retreat

Hims & Hers Health (HIMS) has been at the center of attention after launching a discounted compounded semaglutide weight loss pill, then quickly withdrawing it following legal threats from Novo ...
Stocktwits on MSN

Novo Nordisk sues Hims & Hers over compounded Wegovy, calls for permanent sales ban: HIMS stock tanks

Novo also stated that Hims & Hers is duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs. ・Last week, the U.S. Food and Drug Administration ...

Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (4 Ratings)

Insights from analysts' 12-month price targets are revealed, presenting an average target of $40.5, a high estimate of $60.00, and a low estimate of $21.00. Highlighting a 27.03% decrease, the current ...

What analysts think of Novo, Him & Hers after obesity pill withdrawal

As Novo Nordisk surges and Hims & Hers tanks, analysts see relief for Novo from competition in the compounded pill segment ...

Novo Nordisk Accuses Hims & Hers of ‘Illegal Mass Compounding’ Over Cheaper Wegovy Version

Hims & Hers said it would begin offering copies of Wegovy for an introductory price of $49 for the first month with a ...

Hims & Hers: GLP-1 Revenues Can't Be Relied On

Hims & Hers Health, Inc. is in trouble. The telehealth platform's compounded GLP-1 weight loss drugs are under the FDA’s and ...